Pharma Pulse 7/4/24: Semaglutide Associated with Optic Neuropathy That Can Lead to Blindness, FDA Approves Lilly’s Kisunla & more

FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease

Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.

Semaglutide Associated With Optic Neuropathy That Can Lead to Blindness, Mass Eye and Ear Researchers Report

The active ingredient in Ozempic and Wegovy is linked to nonarteritic anterior ischemic optic neuropathy (NAION), the second most common form of optic neuropathy. This is apparently the first study to link semaglutide to the eye condition.

Approval of Newest Alzheimer’s Drug Will Accelerate New Era of Treatment

With the arrival of Lilly’s Kisunla, Alzheimer’s care could become more like treatment of cancer and rheumatoid arthritis and their regular infusions.

Boys & Girls Clubs of America and “The Chi” Star Jacob Latimore Team up to Host Mental Health Panel for Atlanta Youth

Boys & Girls Clubs of America, in collaboration with Kohl’s, hosted a mental health panel and discussion about challenges young people face, featuring actor, musician and dancer Jacob Latimore and youth from Atlanta-area Boys & Girls Clubs. The event on June 29 culminated National Boys & Girls Club Week celebrations and provided a platform for young people to engage in open, authentic conversations about mental health challenges and successes experienced within different communities.

FDA on Threads

The 4th of July is the day of the year that pets are most likely to go missing.

Loud sounds, crowds, and flashing lights may contribute to overwhelming anxiety that can make pets run away.

If you can’t keep your pet inside during the fireworks, make sure they have ID tags and are microchipped in case they run away in the chaos.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs